Compositions for inducing an immune response against zika virus

Patent metadata

Field	Value
Publication number	US-12161709-B2
Application number	US-202117559190-A
Country	US
Kind code	B2
Filing date	Dec 22, 2021
Priority date	Jan 11, 2017
Publication date	Dec 10, 2024
Grant date	Dec 10, 2024

Abstract

The present invention relates to compositions and methods for inducing an adaptive immune response against Zika virus (ZIKV) in a subject. In certain embodiments, the present invention provides a composition comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof. For example, in certain embodiments, the composition comprises a vaccine comprising a nucleoside-modified nucleic acid molecule encoding a ZIKV antigen, adjuvant, or a combination thereof.

First claim

What is claimed is:

1. A composition for inducing an immune response against Zika virus (ZIKV) in a subject, the composition comprising at least one mRNA molecule encoding at least one ZIKV antigen, wherein the mRNA molecule comprises a sequence having at least 95% identity to the nucleotide sequence of SEQ ID NO: 1.

2. The composition of claim 1 , wherein the composition further comprises an adjuvant.

3. The composition of claim 1 , wherein the mRNA molecule further encodes at least one adjuvant.

4. The composition of claim 1 , further comprising a lipid nanoparticle (LNP).

5. The composition of claim 1 , wherein the at least one mRNA molecule is encapsulated within an LNP.

6. The composition of claim 1 , wherein the composition is a vaccine.

7. A method of inducing an adaptive immune response against Zika virus (ZIKV) in a subject comprising administering to the subject an effective amount of the composition of claim 1 .

8. The method of claim 7 , wherein the method further comprises administering to the subject an effective amount of an adjuvant.

9. The method of claim 7 , wherein the at least one mRNA molecule is encapsulated within an LNP.

10. The method of claim 7 , wherein the composition is a vaccine.

11. The method of claim 7 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscular.

12. The method of claim 7 , wherein the method comprises a single administration of the composition.

13. The method of claim 7 , wherein the method comprises multiple administrations of the composition.

14. A method of treating or preventing an infection, disease, or disorder associated with ZIKV in at least one selected from the group consisting of the subject and an unborn child of the subject, the method comprising administering to the subject the composition of claim 1 .

15. The method of claim 14 , wherein the at least one mRNA molecule comprises at least one modified nucleoside selected from the group consisting of pseudouridine, and 1-methyl-pseudouridine.

16. The method of claim 14 , wherein the composition further comprises an adjuvant.

17. The method of claim 14 , wherein the at least one mRNA molecule further encodes at least one adjuvant.

18. The method of claim 14 , further comprising a lipid nanoparticle (LNP).

19. The method of claim 14 , wherein the at least one mRNA is encapsulated within an LNP.

20. The method of claim 14 , wherein the composition is a vaccine.

21. The method of claim 14 , wherein the composition is administered by a delivery route selected from the group consisting of intradermal, subcutaneous, inhalation, intranasal, and intramuscular.

22. The method of claim 14 , wherein the method comprises a single administration of the composition.

23. The method of claim 14 , wherein the method comprises multiple administrations of the composition.

Assignees

• Univ Pennsylvania

Inventors

• Weissman Drew
• Pardi Norbert
• Hogan Michael

Classifications

• C12N2770/24134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• A61K2039/55555

  Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers · CPC title

• A61K2039/55511

  Organic adjuvants · CPC title

• A61K2039/55

  characterised by the host/recipient, e.g. newborn with maternal antibodies · CPC title

• A61K2039/545

  characterised by the dose, timing or administration schedule · CPC title